HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr. Pegram on the DESTINY-Breast01 Trial With Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

Mark D. Pegram, MD, discusses the results of the phase 2 DESTINY-Breast01 study examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Dr. Brufsky on Treatment Approaches for Early-Stage HER2+ Breast Cancer

August 27th 2020

Adam M. Brufsky, MD, PhD, discusses the treatment of early-stage, HER2-positive breast cancer.

Trastuzumab Deruxtecan, Tucatinib Generate Excitement in Metastatic HER2+ Breast Cancer

August 27th 2020

Erika P. Hamilton, MD, discusses the pivotal data that led to the approvals of trastuzumab deruxtecan and tucatinib in metastatic HER2-positive breast cancer, factors considered in terms of treatment selection, and emerging agents under exploration.

Dr. Gradishar on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

William J. Gradishar, MD, discusses the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and stable brain metastases.

Tripathy Navigates Ever-Changing HER2+ Breast Cancer Treatment Landscape

August 19th 2020

Debu Tripathy, MD, discusses tucatinib and fam-trastuzumab deruxtecan-nxki as 2 exciting drug approvals in the constantly changing HER2-positive breast cancer treatment paradigm.

Dr. Hamilton on the Promise of Tucatinib in HER2+ Breast Cancer Brain Metastases

August 18th 2020

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

Dr. O’Shaughnessy on the Utility of Tucatinib in the HER2+ Breast Cancer Brain Metastases

August 18th 2020

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

August 18th 2020

Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Antibody-Drug Conjugates in HER2-Positive Breast Cancer

August 14th 2020

Novel antibody-drug conjugates introduce promising options for the management of patients with HER2-positive breast cancer; however, management of drug-related toxicities and optimal sequencing of HER2-targeted therapies remains an ongoing challenge.

Adjuvant T-DM1 Shows Consistent Benefit in Residual Invasive HER2+ Breast Cancer, Irrespective of Mutational Status

August 14th 2020

Ado-trastuzumab emtansine demonstrated a consistent invasive disease-free survival benefit versus trastuzumab in patients with HER2-positive breast cancer across all biomarker subgroups evaluated in the pivotal phase 3 KATHERINE trial.

Dr. Hurvitz on Unmet Needs in HER2+ Breast Cancer

August 12th 2020

Sara A. Hurvitz, MD, discusses unmet needs within the field of HER2-positive breast cancer.

Dr. Tripathy on Trastuzumab Deruxtecan Versus T-DM1 in HER2-Expressing Breast Cancers

August 10th 2020

Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.

Dr. Hurvitz on the Lack of Predictive Biomarkers in HER2+ Breast Cancer

August 7th 2020

Sara A. Hurvitz, MD, discusses the lack of predictive biomarkers in HER2-positive breast cancer.

Dr. Czerniecki on the Benefit of Tucatinib in HER2+ Breast Cancer and Brain Metastases

August 6th 2020

Brian Czerniecki, MD, PhD, discusses the benefit of tucatinib in patients with HER2-positive breast cancer and brain metastases.

FDA Approves Companion Diagnostic for Trastuzumab in HER2+ Breast Cancer

July 29th 2020

The FDA has approved the new VENTANA HER2 Dual ISH DNA Probe Cocktail test for use as a companion diagnostic for trastuzumab and to detect HER2 mutations in patients with breast cancer.

Brufsky Spotlights Data With Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

July 20th 2020

Adam M. Brufsky, MD, PhD, further discusses the utility of trastuzumab deruxtecan in HER2-positive breast cancer, ongoing research efforts examining the antibody–drug conjugate, and how he approaches sequencing in the paradigm.

Key Data Inform Treatment Decisions in Early HER2+ Breast Cancer

July 17th 2020

The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.

Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach

July 17th 2020

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.

Trastuzumab Deruxtecan Shows “Remarkable” Responses in HER2+ Breast Cancer, Requires Monitoring of Respiratory Symptoms

July 16th 2020

Charles E. Geyer, Jr, MD, discusses the state of HER2-positive breast cancer, the significance of the results of the DESTINY-Breast01 trial, and symptoms that could be an early indicator of interstitial lung disease.

Dr. Lin on the Treatment Landscape in HER2+ Metastatic Breast Cancer

July 16th 2020

Nancy U. Lin, MD, discusses the treatment landscape in HER2-positive metastatic breast cancer.